GGrantIndex
← Search

URSODEOXYCHOLIC ACID--METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS

$34,535M01FY2000RRNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Abstract

This is a multicenter, prospective, randomized, double-blind placebo-controlled clinical trial to assess whether methotrexate (MTX) improved the therapeutic efficacy of ursodeoxycholic acid (UCA) in the treatment of patients with Primary Biliary Cirrhosis (PBC).

View original record on NIH RePORTER →